Skip to main content

Table 1 Characteristics of the enrolled population

From: Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study

Patients analyzed at visit 1 N = 20
Age (median, IQR) (years) 42 (39–49)
Gender (female) 12 (60%)
Race (Caucasian) 19 (95%)
Age at HAE diagnosis (median, IQR) (years) 18.5 (13–32)
HAE etiology (% type 1) 20 (100%)
Patients under prophylactic treatment (total) 6 (30%)
• Androgens 5 (83.3%)
• Antifibrinolytics 1 (16.7%)
• Pnf C1-INH 0 (0%)
Treatment used by patients for acute attacks before the study
• Pnf C1-INH 18 (90%)
• Icatibant 12 (60%)